Compare Charles River Laboratories Intl. Inc (CRL) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Alphabet Inc Class A — how do they compare? Charles River Laboratories Intl. Inc trades at $231.68 (market cap $11.14B), while Alphabet Inc Class A trades at $368.02 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 392.3× Charles River Laboratories Intl. Inc's market cap, and Alphabet Inc Class A pays a 0.24% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | GOOGL | |
|---|---|---|
Market Cap | $11.14B | $4.37T |
Sector | Health | Media |
52-Week High | $233.60 | $402.62 |
52-Week Low | $145.57 | $182.00 |
Enterprise Value | $14.00B | $4.34T |
Dividend Yield | — | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Alphabet (GOOGL) trades at $367.14, up 4.15% today, with a neutral technical signal and strong fundamentals. The stock shows robust profitability with a 37.92% net margin and consistent earnings beats, including Q1 2026 EPS of $5.11 versus $2.64 expected. Revenue grew to $402.84B in 2025, and operating cash flow surged to $164.71B. Analysts are overwhelmingly bullish with an 85.19% buy rating and a $431.78 consensus price target. Recent news highlights AI-driven growth opportunities, including partnerships and YouTube subscription price increases.
The outlook for GOOGL remains positive, supported by AI expansion and solid financials, but risks include antitrust scrutiny and market volatility. The stock offers upside to analyst targets, though investors should monitor competitive pressures and regulatory developments that could impact growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
